Skip to main content

Table 4 Characteristics of patients who did or did not receive full course of trastuzumab

From: Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy

  Full course received (n = 46) Incomplete course (n = 68) P value
Year of diagnosis    0.725
 2010 6 (13%) 14 (21%)  
 2011 18 (39%) 21 (31%)  
 2012 14 (30%) 21 (31%)  
 2013 8 (17%) 12 (18%)  
Location    0.003
 4o care centre 16 (35%) 8 (12%)  
 Peripheral centre 30 (65%) 60 (88%)  
Age at diagnosis 56 years ±11 57 years ±10 0.556
T    0.395
 0 1 (2%) 0  
 1 13 (28%) 28 (42%)  
 2 23 (50%) 30 (45%)  
 3 3 (7%) 2 (3%)  
 4 6 (13%) 7 (10%)  
N    0.0002
 0 14 (31%) 39 (58%)  
 1 23 (51%) 20 (30%)  
 2 3 (7%) 5 (7%)  
 3 5 (11%) 3 (4%)  
Mastectomy 43 (93%) 53 (78%) 0.026
Radiation 37 (80%) 50 (74%) 0.395
Radiation dose (Gy) 80 (42.5,95) 52.5 (0,85.25) 0.074
Anthracycline dose 240 mg/m2 (240,240) 240 mg/m2 (150,240) 0.148
Pre-existing CVD 2 (4%) 4 (6%) 1.0
CV risk factors 21 (46%) 36 (53%) 0.445
Baseline LVEF 62% ±6 60% ±6 0.251
LVEF at time of deterioration 47% (45,48) 45% (42,47.5) 0.005
Symptoms of HF 7 (15%) 20 (30%) 0.080
Cardiology consult 26 (57%) 49 (72%) 0.086
  1. Values shown are counts (percentages), mean ± SD, or median (Q1, Q3). Abbreviations: CV Cardiovascular, CVD Cardiovascular disease, HF Heart failure, LVEF Left ventricular ejection fraction, N Nodal stage, T Tumour stage